Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 16713481.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This article reports on the combined use of alefacept and etanercept in 3 patients whose psoriasis failed to respond adequately to etanercept. All patients maintained improvement for at least 8 weeks after completing 12 weeks of alefacept. No adverse events or infections were reported, and CD4+ T-cell counts remained above normal limits.
Medical subject headings
- Immunoglobulin G
- Psoriasis
- Receptors, Tumor Necrosis Factor
- Recombinant Fusion Proteins